Impulse control disorders in Parkinson's disease: Decreased striatal dopamine transporter levels

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 2, 2014, Pages 148-152

  Voon, Valerie ^a,b,c   Rizos, Alexandra ^d   Chakravartty, Riddhika ^d   Mulholland, Nicola ^d   Robinson, Stephanie ^d   Howell, Nicholas A ^a,e   Harrison, Neil ^e   Vivian, Gill ^d   Chaudhuri, K Ray ^d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c CAMBRIDGESHIRE AND PETERBOROUGH NHS FOUNDATION TRUST   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; IOFLUPANE; IOMETOPANE I 123; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; FEMALE; HEMISPHERIC DOMINANCE; HUMAN; IMPULSE CONTROL DISORDER; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; REGULATORY MECHANISM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYNAPSE;

BEHAVIOURAL DISORDER; FUNCTIONAL IMAGING; MOVEMENT DISORDERS; NEUROPSYCHIATRY; SPECT;

CASE-CONTROL STUDIES; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IMPULSE CONTROL DISORDERS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PARKINSON DISEASE; TROPANES;

EID: 84893432215     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-305395     Document Type: Article

References (35)

1. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010;67:589-95.
2. Steeves TD, Miyasaki J, Zurowski M, et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009;132:1376-85.
3. O'Sullivan SS, Wu K, Politis M, et al. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain 2011;134:969-78.
4. Voon V, Pessiglione M, Brezing C, et al. Mechanisms underlying dopaminemediated reward bias in compulsive behaviors. Neuron 2010;65:135-42.
5. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006;59:852-8. (Pubitemid 43673163)
6. Cilia R, Ko JH, Cho SS, et al. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. Neurobiol Dis 2010;39:98-104.
7. Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 2007;64:1089-96. (Pubitemid 47258066)
8. Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-53.
9. Steeves TD, Ko JH, Kideckel DM, et al. Extrastriatal dopaminergic dysfunction in tourette syndrome. Ann Neurol 2010;67:170-81.
10. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004;19:397-405. (Pubitemid 38559642)
11. Voon V, Sohr M, Lang AE, et al. Impulse control disorders in Parkinson disease: a multicenter case-control study. Ann Neurol 2011;69:986-96.
12. Vallelunga A, Flaibani R, Formento-Dojot P, et al. Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders. Parkinsonism Relat Disord 2012;18:397-9.
13. Sekine Y, Iyo M, Ouchi Y, et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 2001;158:1206-14. (Pubitemid 32717692)
14. McCann UD, Wong DF, Yokoi F, et al. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 1998;18:8417-22. (Pubitemid 28465016)
15. Volkow ND, Chang L, Wang GJ, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 2001;21:9414-8. (Pubitemid 33096884)
16. Laine TP, Ahonen A, Torniainen P, et al. Dopamine transporters increase in human brain after alcohol withdrawal. Molecular psychiatry. 1999;4:189-91, 04-5. (Pubitemid 29163983)
17. Crits-Christoph P, Newberg A, Wintering N, et al. Dopamine transporter levels in cocaine dependent subjects. Drug Alcohol Depend 2008;98:70-6.
18. Malison RT, Best SE, van Dyck CH, et al. Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT. Am J Psychiatry 1998;155:832-4. (Pubitemid 28252667)
19. Jacobsen LK, Staley JK, Malison RT, et al. Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. Am J Psychiatry 2000;157:1134-40. (Pubitemid 30432496)
20. Volkow ND, Wang GJ, Fischman MW, et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997;386:827-30. (Pubitemid 27181255)
21. Guttman M, Stewart D, Hussey D, et al. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001;56:1559-64. (Pubitemid 32544560)
22. Ahlskog JE, Uitti RJ, O'Connor MK, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord 1999;14:940-6.
23. Innis RB, Marek KL, Sheff K, et al. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord 1999;14:436-42. (Pubitemid 30011653)
24. Schmitt KC, Reith ME. Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Ann NY Acad Sci 2010;1187:316-40.
25. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010;67:58-63.
26. Voon V, Fernagut PO, Wickens J, et al. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol 2009;8:1140-9.
27. Chernoloz O, El Mansari M, Blier P. Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain. Neuropsychopharmacology 2009;34:651-61.
28. Harden DG, Grace AA. Activation of dopamine cell firing by repeated L-DOPA administration to dopamine-depleted rats: its potential role in mediating the therapeutic response to L-DOPA treatment. J Neurosci 1995;15:6157-66.
29. Grace AA. Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia. Neuropharmacology 2012;62:1342-8.
30. Ray NJ, Miyasaki JM, Zurowski M, et al. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. Neurobiolo Dis 2012;48:519-25.
31. Nirenberg MJ, Vaughan RA, Uhl GR, et al. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci 1996;16:436-47. (Pubitemid 26028804)
32. Schneider JS, Rothblat DS, DiStefano L. Volume transmission of dopamine over large distances may contribute to recovery from experimental parkinsonism. Brain Research 1994;643:86-91. (Pubitemid 24115080)
33. Sulzer D, Chen TK, Lau YY, et al. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 1995;15:4102-8.
34. Sulzer D, Sonders MS, Poulsen NW, et al. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005;75:406-33. (Pubitemid 40834286)
35. Laruelle M, Baldwin RM, Malison RT, et al. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993;13:295-309. (Pubitemid 23104535)